Issues and Prospects of microRNA-Based Biomarkers in Blood and Other Body Fluids

Chevillet, John R.; Lee, Inyoul; Briggs, Hilary; He, Yuqing; Wang, Kai

doi:10.3390/molecules19056080

Cited by 107 publications

(88 citation statements)

References 175 publications

(186 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These need to be standardised to allow the study of circulating miRNAs. Even though there are recent reports that seem to address this issue, to the best of our knowledge no global consensus exists at this time [72,75,76].…”

Section: Current Limits To the Use Of Circulating Mirnas In Clinical mentioning

confidence: 99%

“…Finally, the patterns of circulating miRNAs in diabetes can be changed by a wide range of associated conditions such as cancer [93], and cardiovascular, neurodegenerative, metabolic [72] and autoimmune diseases [94].…”

Section: Current Limits To the Use Of Circulating Mirnas In Clinical mentioning

confidence: 99%

“…The method of RNA isolation can affect the miRNA profile depending on the protocol chosen for either total RNA or specific miRNA purification [72]. The most commonly used miRNA profiling assays are from Applied Biosystems (Taqman technology) and Exiqon (LNA technology).…”

Section: Current Limits To the Use Of Circulating Mirnas In Clinical mentioning

confidence: 99%

See 2 more Smart Citations

Circulating microRNAs and diabetes: potential applications in medical practice

et al. 2015

View full text Add to dashboard Cite

The explosive increase in the worldwide prevalence of diabetes over recent years has transformed the disease into a major public health concern. While diabetes can be screened for and diagnosed by reliable biological tests based on blood glucose levels, by and large there are no means of detecting at-risk patients or of following diabetic complications. The recent discovery that microRNAs are not only chief intracellular players in many biological processes, including insulin secretion and action, but are also circulating, has put them in the limelight as possible biological markers. Here we discuss the potential role of circulating microRNAs as biomarkers in the context of diabetes and its associated complications.

show abstract

Section: Current Limits To the Use Of Circulating Mirnas In Clinical mentioning

confidence: 99%

Section: Current Limits To the Use Of Circulating Mirnas In Clinical mentioning

confidence: 99%

See 1 more Smart Citation

Circulating microRNAs and diabetes: potential applications in medical practice

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The measurement of miRNA expression by digital PCR could circumvent normalization, being an absolute method of nucleic-acid quantification. In this respect, droplet digital PCR (ddPCR), a highly precise method and not reliant on reference standard curves, has recently been shown to reduce analytic variability and to improve day-to-day reproducibility compared to RT-qPCR (14).…”

Section: Status Of Circulating Mirna Biomarkersmentioning

confidence: 99%

“…Addition of spike-in standards prior to cDNA synthesis and PCR can estimate efficiency and normalise results for comparison (14). The measurement of miRNA expression by digital PCR could circumvent normalization, being an absolute method of nucleic-acid quantification.…”

Section: Status Of Circulating Mirna Biomarkersmentioning

confidence: 99%

Circulating microRNAs as emerging non-invasive biomarkers for gliomas

Santangelo¹,

Tamanini²,

Cabrini³

et al. 2017

Ann. Transl. Med.

View full text Add to dashboard Cite

No single circulating biomarker has been put to practice for malignant gliomas so far, the most lethal primary brain tumors. Many promising protein biomarkers such as the mutant EGFRvIII or glial fibrillary acidic protein (GFAP) have already been detected in the blood and cerebrospinal fluid (CSF) of patients with gliomas, but their clinical value is still pending validation. Furthermore, these and other proteins seem to lack sufficient sensitivity and specificity required for a successful biomarker in this clinical setting. The expression profiling of microRNAs (miRNAs) has already entered cancer clinics as diagnostic and prognostic biomarkers, for assessing tumor initiation, progression and response to treatment. Largescale miRNA expression analyses reported both up-regulation and down-regulation of several miRNAs in tumour tissues from patients with gliomas compared to normal brain tissue, thus supporting the development of miRNA-based biomarkers. Using comprehensive high-throughput approaches, such as microarrays, different circulating miRNAs were proposed as potential biomarkers of gliomas. This review is aimed to summarize the clinical evidence about circulating miRNA biomarkers discovered to date. Mandatory issues to develop clinically validated biomarkers to improve time of diagnosis, predicting response to treatment and prognosis of patients with gliomas are also herein addresses.

show abstract

A review of highly sensitive electrochemical genosensors for microRNA detection: A novel diagnostic platform for neurodegenerative diseases diagnostics

Taheri‐Anganeh

Mahdavian

Dorosti

et al. 2022

Biotech and App Biochem

View full text Add to dashboard Cite

The significant role of microRNAs in regulating gene expression and in disease tracking has handed the possibility of robust and accurate diagnosis of various diseases. Measurement of these biomarkers has also had a significant impact on the preparation of natural samples. Discovery of miRNAs is a major challenge due to their small size in the real sample and their short length, which is generally measured by complex and expensive methods. Electrochemical nanobiosensors have made significant progress in this field. Due to the delicate nature of nerve tissue repair and the significance of rapid‐fire feature of neurodegenerative conditions, these biosensors can be reliably promising. This review presents advances in the field of neurodegenerative diseases diagnostics. At the same time, there are still numerous openings in this field that are a bright prospect for researchers in the rapid‐fire opinion of neurological diseases and indeed nerve tissue repair.

show abstract

Issues and Prospects of microRNA-Based Biomarkers in Blood and Other Body Fluids

Cited by 107 publications

References 175 publications

Circulating microRNAs and diabetes: potential applications in medical practice

Circulating microRNAs and diabetes: potential applications in medical practice

Circulating microRNAs as emerging non-invasive biomarkers for gliomas

A review of highly sensitive electrochemical genosensors for microRNA detection: A novel diagnostic platform for neurodegenerative diseases diagnostics

Contact Info

Product

Resources

About